Your browser is no longer supported. Please, upgrade your browser.
Settings
YMAB [NASD]
Y-mAbs Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.98 Insider Own30.55% Shs Outstand41.87M Perf Week-0.03%
Market Cap1.25B Forward P/E- EPS next Y-1.53 Insider Trans-2.46% Shs Float26.95M Perf Month25.24%
Income-119.30M PEG- EPS next Q-0.80 Inst Own58.30% Short Float11.13% Perf Quarter-28.37%
Sales20.80M P/S59.98 EPS this Y-29.20% Inst Trans0.81% Short Ratio8.58 Perf Half Y-29.88%
Book/sh6.02 P/B5.68 EPS next Y-4.00% ROA-33.30% Target Price57.75 Perf Year-5.24%
Cash/sh6.91 P/C4.94 EPS next 5Y- ROE-38.50% 52W Range24.77 - 55.22 Perf YTD-30.94%
Dividend- P/FCF- EPS past 5Y- ROI-113.40% 52W High-38.08% Beta-
Dividend %- Quick Ratio15.50 Sales past 5Y- Gross Margin- 52W Low38.00% ATR2.12
Employees125 Current Ratio15.50 Sales Q/Q- Oper. Margin- RSI (14)61.50 Volatility8.77% 6.95%
OptionableYes Debt/Eq0.00 EPS Q/Q214.30% Profit Margin- Rel Volume0.62 Prev Close32.75
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume349.45K Price34.19
Recom1.80 SMA2017.60% SMA5011.04% SMA200-15.71% Volume215,708 Change4.40%
May-07-21Upgrade BofA Securities Neutral → Buy
Apr-23-21Resumed Cowen Outperform
Mar-22-21Resumed JP Morgan Overweight $57 → $52
Jan-15-21Downgrade BofA Securities Buy → Neutral $56
Nov-09-20Reiterated H.C. Wainwright Buy $52 → $65
May-05-20Initiated Barclays Overweight $44
May-01-20Initiated Janney Buy
Apr-29-20Initiated Morgan Stanley Equal-Weight
Dec-24-19Initiated JP Morgan Overweight $39
Nov-20-19Initiated Guggenheim Buy
Sep-04-19Initiated Wedbush Outperform
Apr-01-19Initiated H.C. Wainwright Buy $36
Oct-16-18Initiated BTIG Research Buy $35
Oct-16-18Initiated BofA/Merrill Buy $26
May-13-21 09:00AM  
May-07-21 07:15AM  
May-06-21 05:50PM  
04:01PM  
Apr-29-21 04:01PM  
09:00AM  
Apr-27-21 04:01PM  
Apr-23-21 07:27AM  
Apr-20-21 12:18PM  
09:00AM  
Apr-12-21 09:00AM  
Apr-09-21 10:24AM  
Feb-28-21 11:46PM  
Feb-26-21 06:45AM  
Feb-25-21 04:01PM  
04:50AM  
Feb-22-21 04:01PM  
Feb-19-21 09:00AM  
Feb-18-21 05:20AM  
Feb-17-21 07:14PM  
Feb-16-21 04:01PM  
Jan-06-21 09:00AM  
Dec-28-20 09:00AM  
Dec-18-20 09:05AM  
09:00AM  
Dec-16-20 09:00AM  
Dec-10-20 04:50PM  
Dec-09-20 09:00AM  
Dec-07-20 09:00AM  
Dec-04-20 12:06PM  
09:00AM  
Nov-25-20 05:02PM  
Nov-19-20 09:00AM  
Nov-06-20 04:01PM  
Nov-05-20 04:01PM  
Oct-29-20 09:00AM  
Oct-28-20 03:02PM  
Oct-26-20 09:10AM  
Oct-16-20 09:00AM  
Oct-14-20 09:00AM  
Oct-09-20 09:00PM  
Oct-08-20 05:34PM  
01:05PM  
Oct-07-20 09:00AM  
Oct-06-20 08:24AM  
Oct-05-20 04:01PM  
Aug-06-20 04:01PM  
09:00AM  
Aug-04-20 09:00AM  
Jul-27-20 04:01PM  
Jul-14-20 09:00AM  
Jul-05-20 03:05PM  
Jun-30-20 04:01PM  
Jun-02-20 09:00AM  
May-22-20 11:58AM  
May-13-20 09:00AM  
May-11-20 06:53AM  
May-09-20 02:00PM  
May-07-20 04:01PM  
12:26PM  
Apr-30-20 09:56AM  
09:00AM  
Apr-28-20 12:51PM  
Apr-24-20 09:00AM  
Apr-15-20 09:22AM  
Apr-01-20 09:00AM  
Mar-12-20 04:01PM  
02:30PM  
Mar-05-20 09:00AM  
Feb-26-20 04:01PM  
Jan-07-20 09:00AM  
Dec-24-19 08:13AM  
Dec-16-19 01:48PM  
Dec-12-19 09:00AM  
Dec-11-19 09:00AM  
Dec-05-19 04:01PM  
09:00AM  
Nov-29-19 09:00AM  
Nov-15-19 09:03AM  
Nov-13-19 04:01PM  
Nov-06-19 04:05PM  
Nov-01-19 04:05PM  
11:00AM  
Oct-30-19 08:20PM  
Oct-29-19 09:14PM  
04:40PM  
07:32AM  
Oct-28-19 10:42AM  
09:00AM  
Oct-25-19 09:14AM  
Sep-04-19 03:09PM  
Aug-30-19 09:00AM  
Aug-14-19 10:23PM  
04:05PM  
Aug-08-19 01:36PM  
Aug-07-19 04:15PM  
Jul-08-19 09:00AM  
Jul-01-19 09:01AM  
09:00AM  
Jun-26-19 09:00AM  
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gad ThomasSee remarksApr 26Option Exercise2.007,00014,0007,000Apr 28 04:16 PM
Gad ThomasSee remarksApr 26Sale27.967,000195,7300Apr 28 04:16 PM
Gad ThomasSee remarksApr 12Option Exercise2.007,00014,0007,000Apr 14 05:00 PM
Gad ThomasSee remarksApr 12Sale26.604,000106,3881,611,927Apr 14 05:00 PM
Gad ThomasSee remarksApr 12Sale26.617,000186,2530Apr 14 05:00 PM
Gad ThomasSee remarksApr 01Option Exercise2.009,00018,0009,000Apr 05 04:35 PM
Gad ThomasSee remarksApr 01Sale30.276,000181,6151,615,927Apr 05 04:35 PM
Gad ThomasSee remarksApr 01Sale30.269,000272,3310Apr 05 04:35 PM
Gad ThomasSee remarksMar 15Option Exercise2.007,00014,0007,000Mar 17 04:35 PM
Gad ThomasSee remarksMar 15Sale36.784,000147,1021,621,927Mar 17 04:35 PM
Gad ThomasSee remarksMar 15Sale36.797,000257,5540Mar 17 04:35 PM
Gad ThomasSee remarksMar 01Option Exercise2.009,00018,0009,000Mar 03 04:31 PM
Gad ThomasSee remarksMar 01Sale35.506,000213,029596,000Mar 03 04:31 PM
Gad ThomasSee remarksMar 01Sale35.519,000319,6110Mar 03 04:31 PM
Gad ThomasSee remarksFeb 16Option Exercise2.007,00014,0007,000Feb 18 04:35 PM
Gad ThomasSee remarksFeb 16Sale47.094,000188,367602,000Feb 18 04:35 PM
Gad ThomasSee remarksFeb 16Sale47.087,000329,5560Feb 18 04:35 PM
Gad ThomasSee remarksFeb 01Option Exercise2.007,00014,0007,000Feb 03 05:50 PM
Gad ThomasSee remarksFeb 01Sale41.974,000167,888606,000Feb 03 05:50 PM
Gad ThomasSee remarksFeb 01Sale41.997,000293,8970Feb 03 05:50 PM
GILL DAVID NDirectorJan 19Option Exercise11.162,00022,3202,000Jan 20 04:16 PM
Gad ThomasSee remarksJan 19Option Exercise2.007,00014,0007,000Jan 21 04:16 PM
Gad ThomasSee remarksJan 19Sale46.564,000186,230610,000Jan 21 04:16 PM
Gad ThomasSee remarksJan 19Sale46.517,000325,5630Jan 21 04:16 PM
GILL DAVID NDirectorJan 19Sale46.522,00093,0450Jan 20 04:16 PM
Gad ThomasSee remarksJan 05Option Exercise2.007,00014,0007,000Jan 07 04:15 PM
Gad ThomasSee remarksJan 05Sale49.314,000197,248614,000Jan 07 04:15 PM
Gad ThomasSee remarksJan 05Sale49.367,000345,5090Jan 07 04:15 PM
Gad ThomasSee RemarksDec 28Option Exercise2.007,00014,0007,000Dec 30 04:52 PM
Gad ThomasSee RemarksDec 28Sale51.987,000363,8330Dec 30 04:52 PM
Gad ThomasSee RemarksDec 16Option Exercise2.007,00014,0007,000Dec 17 04:39 PM
Gad ThomasSee RemarksDec 16Sale53.017,000371,0650Dec 17 04:39 PM
Gad ThomasSee RemarksDec 14Sale52.894,000211,546618,000Dec 16 06:06 PM
Gad ThomasSee RemarksDec 11Option Exercise2.0050,000100,00050,000Dec 14 04:30 PM
Gad ThomasSee RemarksDec 11Sale51.1750,0002,558,6400Dec 14 04:30 PM
Gad ThomasSee RemarksDec 10Option Exercise2.0050,000100,00050,000Dec 14 04:30 PM
Gad ThomasSee RemarksDec 10Sale50.7550,0002,537,6200Dec 14 04:30 PM
Moller-San Pedro Claus JuanChief Executive OfficerDec 03Sale50.989,266472,377607,303Dec 04 06:00 AM
Rajah VigneshSVP and CMODec 02Buy51.0323311,8901,697Dec 04 06:00 PM
Moller-San Pedro Claus JuanChief Executive OfficerDec 02Sale51.2740,7342,088,245616,569Dec 04 06:00 AM
Gad ThomasPresident and ChairmanDec 01Sale51.424,000205,685622,000Dec 02 04:15 PM
GILL DAVID NDirectorNov 18Option Exercise11.162,00022,3202,000Nov 20 04:15 PM
GILL DAVID NDirectorNov 18Sale45.772,00091,5300Nov 20 04:15 PM
Rajah VigneshSVP and CMONov 17Buy45.741,46466,9631,464Dec 04 06:00 PM
Gad ThomasPresident and ChairmanNov 16Sale46.174,000184,672626,000Nov 17 04:15 PM
GILL DAVID NDirectorNov 03Option Exercise11.164,00044,6404,000Nov 05 05:51 PM
GILL DAVID NDirectorNov 03Sale45.004,000180,0000Nov 05 05:51 PM
Gad ThomasPresident and ChairmanNov 02Sale43.694,000174,769630,000Nov 05 04:36 PM
Gad ThomasPresident and ChairmanOct 15Sale39.154,000156,604634,000Oct 19 04:15 PM
Gad ThomasPresident and ChairmanOct 01Sale38.884,000155,524638,000Oct 02 05:38 PM
Gad ThomasPresident and ChairmanSep 15Sale40.814,000163,225642,000Sep 17 04:15 PM
Gad ThomasPresident and ChairmanSep 14Option Exercise2.0022,56945,13822,569Sep 15 04:15 PM
Gad ThomasPresident and ChairmanSep 14Sale41.0022,569925,4260Sep 15 04:15 PM
Gad ThomasPresident and ChairmanSep 11Option Exercise2.0013,57127,14213,571Sep 15 04:15 PM
Gad ThomasPresident and ChairmanSep 11Sale40.3313,571547,3310Sep 15 04:15 PM
Gad ThomasPresident and ChairmanSep 10Option Exercise2.0013,86027,72013,860Sep 15 04:15 PM
Gad ThomasPresident and ChairmanSep 10Sale41.5813,860576,3600Sep 15 04:15 PM
Gad ThomasPresident and ChairmanSep 01Sale41.604,000166,390646,000Sep 02 04:15 PM
Gad ThomasPresident and ChairmanAug 17Sale40.354,000161,392650,000Aug 19 04:16 PM
Gad ThomasPresident and ChairmanAug 12Sale39.5113,000513,636654,000Aug 13 04:15 PM
Gad ThomasPresident and ChairmanAug 11Sale40.0637,0001,482,042667,000Aug 13 04:15 PM
Gad ThomasPresident and ChairmanAug 03Sale36.514,000146,026704,000Aug 05 04:25 PM
Gad ThomasPresident and ChairmanJul 15Sale40.064,000160,229708,000Jul 17 04:18 PM
Gad ThomasPresident and ChairmanJul 01Sale42.044,000168,178712,000Jul 06 04:15 PM
Gad ThomasPresident and ChairmanJun 15Sale43.454,000173,811716,000Jun 16 06:14 PM
Gad ThomasPresident and ChairmanJun 04Sale41.614,000166,444720,000Jun 05 04:15 PM
Gad ThomasPresident and ChairmanMay 27Sale39.0150,0001,950,460724,000May 29 04:15 PM
Ahmed MahiuddinSr. VP and CSOMay 26Sale39.3850,0001,969,235150,000May 27 04:15 PM
Ahmed MahiuddinSr. VP and CSOMay 19Sale39.2410,000392,403200,000May 20 04:15 PM
Gad ThomasPresident and ChairmanMay 18Sale39.654,000158,596774,000May 20 04:15 PM
Ahmed MahiuddinSr. VP and CSOMay 18Sale39.4919,492769,675210,000May 20 04:15 PM